Acclime sets up Nacuity Pharmaceuticals for R&D success in Australia.

Acclime’s on-the-ground experts and full range of corporate services enabled Nacuity to successfully advance into the Australian R&D market and join a thriving bioscience ecosystem, as well as develop a strategy for accessing the Australian government’s R&D Tax Incentive program.

The Acclime solution allowed Nacuity to advance its clinical trial program, whilst also:

• Forming valuable connections with key people across the clinical trial ecosystem
• Establishing a network of advisors and world-class experts in the field of ophthalmology in Australia
• Gaining experience and confidence in the US FDA’s acceptance of Australian clinical trial data
• Discovering a high-quality Australian manufacturing partner to save both time and money, and
• Partnering with a highly skilled Australian packaging and distribution firm.

Nacuity was pleased by the opportunities that Acclime opened up for them in the Australian market. They discovered that the Australian clinical trial ecosystem was more highly evolved and much broader than they had anticipated.

Acclime’s work on the Nacuity clinical trial project helped the client achieve:

• More than 12 months saved in both time and costs
• R&D tax incentive benefits
• Access to leading expertise across all aspects of R&D, manufacturing, packaging and distribution

Nacuity is presently planning new trials for additional ophthalmological and neurological conditions in Australia, the US, Iceland and other locations all supported by Australian based companies.